Dose-related adverse eff ects of medications are a major problem in modern medical practice. Th e "correct" dose, based on drug company guidelines in package inserts, may not be correct for many patients. Tablet splitting or dividing has been an accepted practice for many years as a means of obtaining the prescribed dose of medication. As model tablets for this investigation, two batches of lisinopril-hydrochlorothiazide scored tablets labeled to contain /, mg were used. Th e aim of this study was to establish possible infl uence of tablet splitting on content uniformity of lisinopril/hydrochlorthiazide tablets. Determination of the content uniformity of lisinopril and hydrochlorthiazide in our batches, was carried out by HPLC method. Th e results of content uniformity studies for halves of tablets containing combination of lisinopril-hydrochlorthiazide (supposed to contain  of stated /, mg in the whole tablet) were: , ±, and ,±,  (lisinopril); ,±, and ,±, (hydrochlorthiazide) for batch I and II, respectively. We can conclude that the results obtained in this study support an option of tablet splitting, which is very important for obtaining the required dosage when a dosage form of the required strength is unavailable, and for better individualization of the therapy.
Introduction
Dose-related adverse eff ects of medications are a major problem in modern medical practice. The "correct" dose, based on drug company guidelines in package inserts, may not be correct for many patients. Broad variation in drug response among patients is a common phenomenon in clinical practice. The ability to match doses to patients depends on the availability of multiple dose sizes and adequate dose-response information. These are not always provided, so splitting of the tablets is sometimes necessary () . Tablet splitting or dividing has been an accepted practice for many years as a means of obtaining the prescribed dose for medication. Patients may be required to split tablets to (, ) : ◊ obtain the required dosage when a dosage form of the required strength is unavailable ◊ provide appropriate fractional doses in a flexible dosing regimen or in a gradually increasing or decreasing dosage regimen ◊ begin therapy with the lowest possible dose to decrease the incidence of adverse eff ects or to gauge an individual patient's response However, the process of splitting tablets cases a number of problems, some of which are patient related while others are related to the tablet or formulation. Uneven splitting of a tablet may result in significant fluctuations in the administered dose. This may be clinically significant for drugs with a narrow therapeutic range. For many drugs, especially those with long half-lives and/or a wide therapeutic range, dose fluctuations are unlikely to be clinically significant. Removing tablets from foil packaging or exposing uncoated tablet surfaces may increase the rate of degradation of the active substance. Th is has important ramifi cations as the patient may get lower than intended dose and adverse eff ects may be increased by degradation products. Th e tablet dissolution rate and absorption properties may also be aff ected when tablets are split (,,) . Tablets can be split manually into two portions by either breaking with the fi ngers along a scored line, cutting with a knife or using a specially designed tablet splitter. Uneven division of the tablet or a degree of wasting may occur as some tablets crumble or break into more than two parts. Irregularly shaped tablets may be diffi cult to load and may not easily be split into equal halves (,,) . For our study, lisinopril-hydrochlorothiazide scored tablets labeled to contain /, mg were used as a model. Lisinopril and hydrochlorothiazide are combined in an oral formulation for the treatment of hypertension.
Hydrochlorothiazide is a commonly used thiazide diuretic. Lisinopril is an angiotensin-converting enzyme inhibitor. Th e eff ects of hydrochlorothiazide and lisinopril on blood pressure are additive. Th iazide diuretics lower the blood pressure by increasing the excretion of sodium; whereas ACE inhibitors lower blood pressure by blocking the renin-angiotensin system (,,) .
Th e aim of this study was to:
9 determine possible diff erences in friability and tablet hardness testing; 9 accept or exclude their infl uence on mass uniformity according to the friability and tablet hardness results obtained 9 determine mass uniformity of the whole and halved tablets split by diff erent methods 9 determine content uniformity of the whole and halved tablets split by diff erent methods
Materials and Methods

Reagents
The used reagents were all of analytical grade, unless otherwise stated. Lisinopril dihydrate and hydrochlorthiazide working standards, were provided by Merck (Darmstadt, Germany). Acetonitrile and methanol were HPLC grade and provided by J.T. Baker (Deventer, Holland). Sodium dihydrogen phosphate, disodium hydrogen phosphate were provided by Carl Roth GmbH & Co. (Karlsruhe, Germany).
Tablet ingredients
For the tablet formulations the following ingredients were used and provided by diff erent producers: lisinopril dihydrate and hydrochlorthiazide (Merck Darmstadt, Germany), calcium hydrogen phosphate dihydrate, magnesium stearate and mannitol (Riedel-de Haën, Seelze-Hanover, Germany), croscarmellose sodium (FMC Biopolymer, Philadelphia, USA), pregelatinized maize starch (Anheuser Busch, St. Louis, USA).
Tablet preparation
Lisinopril dihydrate, hydrochlorothiazide, calcium hydrogen phosphate dihydrate, pregelatinized maize starch, croscarmellose sodium and mannitol were mixed and sieved. Mannitol was also separately sieved. Th is mixture was granulated with purifi ed water. Th e granulation was dried in fl uid bed to the prescribed moisture content and sieved. Sieved magnesium stearate was added. Tabletting was carried out in a rotary tabletting machine. Both formulation batches ("I" and "II") were prepared under the same technological conditions.
Drug dosage form (tablets) tested
The tablets applied for this study are scored on one side, weighing  mg. Th e tablets are fl at and round, with diameter of , mm and height of , mm. The score line (break mark) applied has the following characteristics: W (width) = , mm, D (depth) = , mm, θ =  o and R (engraving cut radius) = , mm.
Crushing strength testing
The tablet is placed between the jaws, taking into account the shape, the break mark and the inscription. Th e tablet was oriented in the same way with respect to the direction of application of the force. The measurement was carried out on  tablets, taking care that all fragments have been removed before each determination. Th e results are expressed in the values of the forces measured, all expressed in newtons. The crushing strength was determined using hardness tester (type TBH , Erweka, Apparatebau, Germany).
Friability testing
Twenty tablets were placed on a sieve, and any loose dust was removed with the aid of the brush. Th e tablet sample was accurately weight and placed in the drum. It was rotated  times, and the tablets were taken out. Any loose dust from the tablets was removed as before. Th e friability is expressed as the loss of the mass and it is calculated as a percentage of the initial mass. Th e friability was determined using Roche friability tester (Erweka, Apparatebau, Germany).
Breakability test methods 9 Manual method
The following manual breakability test was performed; the tablet was held between the thumb and the index finger of each hand on either side of the score line, with the score line facing upwards and without using the nail. Separation into two halves was done by breaking open the tablet at the score line side (legend: score up-break) (Figure .).
9 Tablet-splitter For this test tablet splitter "Iris" (Ljubljana, Slovenia) was used. Tablet splitter cover was lifted up (Figure a) , the tablet was placed into "V" shaped holder (Figure b) . The cover was firmly brought down and closed to split the tablet (Figure c) . Th e tablets were weighed both before and after splitting and the results were compared using statistical methods.
Content uniformity testing
The following experiment examined the content uniformity of the active ingredient in tablets and was carried out by gradient mode high-performance liquid chromatography (HPLC) method. The system consisted of a pump, injection valve, autosampler and variable wavelength detector (Shimadzu, Kyoto, Japan).
Th e mobile phase consisted of two fractions: A (methanol: phosphate buff er pH , = :, v/v) and B (methanol: acetonitrile: phosphate buffer pH , = ::, v/v). The flow rate was , ml/min, the injection volume  μl, the column temperature  o C and the detection wavelengths  nm (lisinopril) and  nm (hydrochlorthiazide). Phenomenex Luna C- column (mm×,mm×μm) was used throughout the experiments.
Results and Discussion
The results of resistance to crushing of tablets and friability testing per batch are presented in Table  .
Acceptable values of friability (less than ,, upper limit-loss ≤) were obtained for both batches of tablets with suitable hardness values, indicating good mechanical properties that are able to withstand handling. The results of mass loss per breakabilty test method and per batch are presented in Table , Table , Table  and Table  (expressed as  of tablet weight). No regulatory requirements for the maximum loss of mass upon breaking exist up to now. In view of the results reported for loss of mass on breaking () and in line with Ph. Eur. requirements on friability, we consider a loss of  acceptable. All samples (whole and halved tablets) meet this requirement. On the other hand, during "tablet splitter" procedure, small dust particles were produced. Loss of mass for manual method for Batch I and II was , and , respectively. For "tablet splitter" method for Batch I and II loss of mass was , and , respectively. According to the results obtained, we decided to proceed following tests with the tablets broken by manual method. The results of content uniformity studies for whole tablets containing combination of lisinopril-hydrochlorthiazide (/,) are summarized in Table , Table   , which show the percentage of drug present in each tablet (n=), standard deviation (S.D.) and relative standard deviation (R.S.D.) as well, for each formulation batch. We have to point out that content uniformity studies for whole tablets were done for our orientation, and for that reason only three tablet samples were used.
The contents of lisinopril and hidrochlothiazide in each tablet fulfilled pharmacopeial requirements. Th e results of content uniformity studies for halved tablets containing combination of lisinopril-hydrochlorthiazide (supposed to contain  of stated /, mg in the whole tablet) are summarized in Table  and Table  which show the percentage of drug present in each tablet (n=), standard deviation (S.D.) and relative standard deviation (R.S.D.) as well, for each formulation batch. 
Conclusion
9 According to the results obtained, we may conclude that tablets from batch "I" and "II" satisfi ed pharmacopeial requirements concerning crushing strength and friability 9 Application of two breaking method used, showed diff erences in loss of mass.
9 Th e results of content uniformity studies for halved tablets containing combination of lisinopril-hydrochlorthiazide (supposed to contain  of stated /, mg in the whole tablet) were: , ±, and ,±,  (lisinopril); ,±, and ,±, (hydrochlorthiazide) for batch I and II, respectively.
9 We can conclude that the results obtained in this study support an option of tablet splitting, which is very important for obtaining the required dosage when a dosage form of the required strength is unavailable, and for better individualization of the therapy.
